Biotoscana Risk Report

🛡️ Financial & Liquidity

Biotoscana has been involved in significant financial activities, primarily through acquisitions and IPOs, marking important events in its history. These activities suggest a strategy focused on expansion and consolidation within the Latin American market.

• Knight Therapeutics announced the acquisition of Grupo Biotoscana, establishing a growth platform in Latin America 🗓 October 21, 2019.
• Knight Therapeutics described its acquisition as 'transformational' for its operations in Brazil 🗓 October 31, 2019.
• Biotoscana had its IPO alongside Carrefour's Brazil unit, marking a successful entry into the Brazilian market 🗓 July 21, 2017.

⚖️ Legal & Regulatory

Knight Therapeutics has actively pursued regulatory milestones, particularly in Brazil and Mexico, signaling strategic compliance efforts following their acquisition of Biotoscana. These regulatory submissions and approvals illustrate the company's targeted approach to expanding its pharmaceutical offerings across Latin America.

• Knight Therapeutics announced regulatory submission of Fostamatinib in Brazil 🗓 February 21, 2024.
• Knight Therapeutics obtained regulatory approval for Tavalisse® in Mexico 🗓 December 12, 2024.

📜 Innovation & R&D

The company's focus on innovation is evident through its active R&D and regulatory submissions, strengthening its market position and product offerings. This indicates ongoing investment in developing and launching new pharmaceutical products across key Latin American markets.

• Knight Therapeutics announced the launch of Minjuvi® (tafasitamab) in Mexico, highlighting ongoing innovation efforts 🗓 March 26, 2025.